Daewoong Pharma
Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplem… Read more
Daewoong Pharma (069620) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.057x
Based on the latest financial reports, Daewoong Pharma (069620) has a cash flow conversion efficiency ratio of 0.057x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩57.53 Billion) by net assets (₩1.00 Trillion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Daewoong Pharma - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how Daewoong Pharma's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Daewoong Pharma Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Daewoong Pharma ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Beijing Beilu Pharmaceutical
SHE:300016
|
0.032x |
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
-0.542x |
|
Sturm Ruger & Company Inc
NYSE:RGR
|
0.046x |
|
Guangdong Cellwise Microelectronics Co. Ltd.
SHG:688325
|
N/A |
|
AP (Thailand) Public Company Limited
BK:AP-R
|
0.063x |
|
Societe LDC SA
PA:LOUP
|
0.091x |
|
Xizi Clean Energy Equipment Manufacturing Co Ltd
SHE:002534
|
0.030x |
|
HelloFresh SE Bearer Shares
F:HFG
|
0.171x |
Annual Cash Flow Conversion Efficiency for Daewoong Pharma (2007–2024)
The table below shows the annual cash flow conversion efficiency of Daewoong Pharma from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩926.98 Billion | ₩51.49 Billion | 0.056x | -66.35% |
| 2023-12-31 | ₩802.97 Billion | ₩132.57 Billion | 0.165x | +3.52% |
| 2022-12-31 | ₩741.22 Billion | ₩118.21 Billion | 0.159x | +180.10% |
| 2021-12-31 | ₩702.41 Billion | ₩39.99 Billion | 0.057x | -60.80% |
| 2020-12-31 | ₩695.25 Billion | ₩100.98 Billion | 0.145x | +60.35% |
| 2019-12-31 | ₩635.92 Billion | ₩57.60 Billion | 0.091x | +15.90% |
| 2018-12-31 | ₩607.81 Billion | ₩47.50 Billion | 0.078x | -52.52% |
| 2017-12-31 | ₩631.54 Billion | ₩103.94 Billion | 0.165x | +547.03% |
| 2016-12-31 | ₩604.55 Billion | ₩15.38 Billion | 0.025x | -58.87% |
| 2015-12-31 | ₩580.24 Billion | ₩35.89 Billion | 0.062x | +8.59% |
| 2014-12-31 | ₩455.51 Billion | ₩25.95 Billion | 0.057x | -53.94% |
| 2013-12-31 | ₩437.96 Billion | ₩54.16 Billion | 0.124x | +6.17% |
| 2012-12-31 | ₩386.59 Billion | ₩45.02 Billion | 0.116x | -46.45% |
| 2011-12-31 | ₩362.42 Billion | ₩78.82 Billion | 0.217x | +93.60% |
| 2008-12-31 | ₩278.85 Billion | ₩31.33 Billion | 0.112x | +17.33% |
| 2007-12-31 | ₩269.57 Billion | ₩25.81 Billion | 0.096x | -- |